stockrow
Saturday 7 November 2026
Export PLRZ’s income statement to Excel — free account
Polyrizon Ltd.
PLRZ Healthcare Biotechnology
11.05
0.54
−4.66%
Follow PLRZ
Alert me
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
Current Ratio |
0.04 | 0.11 | 10.16 | 29.03 |
Net Debt/EBITDA |
0.04 | (0.25) | 2.16 | 2.11 |
Debt/Assets |
0.00% | 35.78% | 0.00% | 0.00% |
Debt/Equity |
0.00 | (1.05) | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.45 | 0.80 | 0.71 | 1.36 |
Capex/Depreciation |
(0.60) | 0.00 | 0.00 | (0.02) |
| 0.00% | 122.64% | (63.00%) | (25.38%) | |
| 0.00% | (121.09%) | (52.57%) | (24.72%) | |
ROIC |
0.00% | 0.00% | (29.79%) | (45.79%) |
Return on Tangible Assets |
68.88% | 153.44% | (66.82%) | (26.83%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.52 | 0.12 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(1,261.11) | (396.60) | (575.23) | (6.67) |
Cash per Share |
40.00 | 30.28 | 1,280.84 | 18.32 |
Shareholders Equity per Share |
(1,000.00) | (141.06) | 2,650.95 | 30.86 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(1,000.00) | (141.06) | 2,650.95 | 30.86 |
Free Cash Flow |
(1.13) | (0.54) | (1.15) | (4.53) |
Working Capital |
(1.15) | (0.45) | 2.39 | 12.42 |
Capital Expenditures |
0.00 | — | — | (0.01) |
Net Current Asset Value |
(1.39) | (0.70) | 2.39 | 12.42 |
| Other line items | ||||
Quick Ratio |
0.03 | 0.08 | 9.79 | 28.14 |
Depreciation/Fixed assets |
0.31 | 0.33 | 11.80 | 28.50 |
Cash ROIC |
131.37% | (1,074.00%) | (14.63%) | (13.55%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1,257.78) | (396.60) | (575.23) | (6.65) |
Capex per Share |
(3.33) | 0.00 | 0.00 | (0.01) |
Average Assets |
— | 0.55 | 3.05 | 13.49 |
Average Common Equity |
— | (0.55) | 2.55 | 13.14 |
Capex to Sales |
0.00 | — | — | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026